OBJECTIVE: At presentation of prostate cancer, patients with proven lymph node metastasis (N1) are comparatively rare. It is difficult to give prognostic information based on the present literature. The aim of this study was to evaluate the impact of known risk factors in patients with pelvic node involvement and without distant metastasis. METHODS: From the population-based, prospective prostate cancer tumour registry of the South-East Region in Sweden, we collected data on all 181 patients with N1, M0 prostate cancer diagnosed from January 1987 to October 2000 with a follow-up to December 2001. Mean follow-up was 62 months. Pre-operative risk factors as age, T-category, serum PSA, tumour grade and also primary treatment given was correlated to the outcome. RESULTS: Median age at diagnosis was 65 years. Cancer-specific survival was highly variable with 5-year survival of 72%, a median of 8 years and the projected 13-year figure was 31%. T-category, age, PSA or treatment did not affect the outcome while poorly differentiated tumours had a tendency towards lower cancer-specific survival (p=0.0523) when compared to well and moderately differentiated tumours. CONCLUSIONS: This population-based cohort of prostate cancer patients with pelvic node involvement treated principally with non-curative intent had a median cancer-specific survival of 8 years. Preoperatively known risk factors seem to have but a modest impact on the prognosis for patients in this stage of the disease.
OBJECTIVE: At presentation of prostate cancer, patients with proven lymph node metastasis (N1) are comparatively rare. It is difficult to give prognostic information based on the present literature. The aim of this study was to evaluate the impact of known risk factors in patients with pelvic node involvement and without distant metastasis. METHODS: From the population-based, prospective prostate cancer tumour registry of the South-East Region in Sweden, we collected data on all 181 patients with N1, M0 prostate cancer diagnosed from January 1987 to October 2000 with a follow-up to December 2001. Mean follow-up was 62 months. Pre-operative risk factors as age, T-category, serum PSA, tumour grade and also primary treatment given was correlated to the outcome. RESULTS: Median age at diagnosis was 65 years. Cancer-specific survival was highly variable with 5-year survival of 72%, a median of 8 years and the projected 13-year figure was 31%. T-category, age, PSA or treatment did not affect the outcome while poorly differentiated tumours had a tendency towards lower cancer-specific survival (p=0.0523) when compared to well and moderately differentiated tumours. CONCLUSIONS: This population-based cohort of prostate cancerpatients with pelvic node involvement treated principally with non-curative intent had a median cancer-specific survival of 8 years. Preoperatively known risk factors seem to have but a modest impact on the prognosis for patients in this stage of the disease.
Authors: Filip Poelaert; Valérie Fonteyne; Piet Ost; Bart De Troyer; Karel Decaestecker; Gert De Meerleer; Pieter De Visschere; Tom Claeys; Bert Dhondt; Nicolaas Lumen Journal: Strahlenther Onkol Date: 2017-01-18 Impact factor: 3.621
Authors: Kathryn L Penney; Jennifer A Sinnott; Katja Fall; Yudi Pawitan; Yujin Hoshida; Peter Kraft; Jennifer R Stark; Michelangelo Fiorentino; Sven Perner; Stephen Finn; Stefano Calza; Richard Flavin; Matthew L Freedman; Sunita Setlur; Howard D Sesso; Swen-Olof Andersson; Neil Martin; Philip W Kantoff; Jan-Erik Johansson; Hans-Olov Adami; Mark A Rubin; Massimo Loda; Todd R Golub; Ove Andrén; Meir J Stampfer; Lorelei A Mucci Journal: J Clin Oncol Date: 2011-05-02 Impact factor: 44.544
Authors: Giovanni Battista Di Pierro; Pietro Grande; Johann Gregory Wirth; Hansjörg Danuser; Agostino Mattei Journal: Can Urol Assoc J Date: 2015 Mar-Apr Impact factor: 1.862